Daren Wilson
Co-founder and Senior Partner
Daren Wilson is a healthcare commercialisation executive, co-founder and Senior Partner of HealthSeed AG in Zurich, and a former General Manager at Roche.
14 articles
VITAL SIGNSAI Healthcare, September 2026: Medicare paid $1,000 for one AI scan
The FDA authorised two AI devices their makers may keep changing, and Medicare found no benefit category for a cleared device, so it pays nothing for it.
Read →
PERSPECTIVEAI found the drug. Now prove it.
Three AI drug discovery companies at the HealthVC Summit each named a different missing experiment. What AI has already changed in drug R&D, what it has not, and where the capital is going.
Read →
NEWSHealthSeed and Mangold Consultants introduce Venitara, a regulatory platform for medical device companies
HealthSeed and Mangold Consultants are introducing Venitara: AI regulatory tools with senior expert review for medical device, SaMD, and IVD companies.
Read →
NEWSHealthSeed and MIA Solutions form a joint venture to bring ZINOS to hospitals
HealthSeed and MIA Solutions are bringing ZINOS to hospital research units: one clinical trial system, inside the institution, under its own control.
Read →
VITAL SIGNSTwelve CE marks and a September registration cliff
Ten companies took twelve European device certificates in ten days, and the three products that left European markets left because a manufacturer stopped trading, a board stopped funding, and a catheter specification failed.
Read →
VITAL SIGNSHealthTech, September 2026: Sweden's €630m record-system write-off
Two Swedish regions abandoned the same hospital record system after €630m. What worked instead was a nurse with a list and a posted letter.
Read →
VITAL SIGNSAI Drug Discovery, September 2026: the bench became the bottleneck
AI drug discovery, September 2026: the AIntibody benchmark tested protein design methods blind, and ICH M15 now asks six questions of any model.
Read →VITAL SIGNSHealthTech, August 2026: every AI scribe Ontario tested made an error
Oracle, Microsoft and Athenahealth folded the AI scribe into the health record. Ontario tested twenty approved AI scribes and every one produced an error.
Read →VITAL SIGNSMedTech, August 2026: everything that mattered happened after approval
MedTech's opening cycle shows devices clearing approval, then losing on reimbursement, vigilance, and evidence standards: three tests approval cannot predict.
Read →
PERSPECTIVEWhy European Health Companies Stall Before They Scale
Health biotech in the US raised EUR 219bn against Europe's EUR 25bn. The 532-day median wait from approval to reimbursement is a large part of why.
Read →
PROGNOSISThe Approval Is No Longer the Milestone
Healthcare's innovation machinery has outpaced its adoption machinery. RAPID, ACCESS and the EHDS show regulators and payers starting to close the gap.
Read →
VITAL SIGNSThe AI Act deadline moved a year. Three obligations did not
The EU moved the AI Act deadline for AI in medical devices to August 2028, but three obligation sets kept their original dates and are in force today.
Read →REFERENCEEU AI Act deadlines for healthcare AI
The EU AI Act deadlines that apply to healthcare AI and medical devices, what moved to 2028, and which obligations are in force right now.
Read →
PERSPECTIVENorth Africa's Digital Health Moment, and the Gap That Decides It
HealthSeed AG joins Telehealth Connect 2026 in Tunis as a strategic partner. Why the region's growth story will be settled where products meet health systems.
Read →